ESR1 and breast cancer: The expression of Dll1 has been associated with poor prognosis [47] and the tumor-promoting function of Dll1 is exclusive to ERα+ luminal BC, as loss of Dll1 inhibits both tumor growth and invasive potential of luminal BC [47].